Neurology Minute

Dr. Rae Bacharach discusses intravenous or subcutaneous immunoglobulin therapy in immune-mediated neurologic conditions.

Dr. Rae Bacharach discusses important points regarding application of the 2017 McDonald criteria for the diagnosis of MS. 

Dr. Rae Bacharach discusses oligoclonal bands in MS and other conditions and differentiating types of bands.

Dr. Barbara Weissman discusses the main points from her Neurology: Clinical Practice paper on recommendations for neurologists on the CDC’s Guideline on Pediatric Mild Traumatic Brain Injury. 

Dr. Geoffrey Donnan discusses the main takeaways from his study on thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. Read his NEJM article here: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1813046. 

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the third part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the second part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Dr. Philip Insel provides the main findings of his paper on determining clinically meaningful decline in preclinical Alzheimer disease. 

Dr. Sarah Tabrizi discusses the main findings of her study on targeting Huntington expression in patients with Huntington’s Disease. Ready the May 6th article in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the first part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Prof. Gil Wolfe discusses who might and might not be good candidates for thymectomy for non-thymomatous myasthenia gravis in the second part of his interview with Dr. Ted Burns. Read the full study in Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30392-2/fulltext. The study was also covered in Neurology Today, which you can read here: https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2019&issue=03070&article=00004&type=FullText. 

Dr. Orrin Devinsky summarizes his paper on the full spectrum of epilepsies and the North American SUDEP Registry. Listen to this week's full podcast for the entire interview.

Prof. Gil Wolfe summarizes his findings from his study on the long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis. Read the paper in Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30392-2/fulltext.  Additionally, see the Neurology Today article from March 7th featuring the study: https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2019&issue=03070&article=00004&type=FullText. 

Dr. Jeffrey Ratliff discusses neurology residency programs, training, and action by the consortium of residency program directors.

Dr. Ted Burns discusses clinical recognition and diagnosis of MuSK myasthenia gravis.

Dr. Annette Langer-Gould discusses pregnancy and family planning with MS in the third of a three-part series. To learn more, read the article "Pregnancy and Family Planning in Multiple Sclerosis" by Dr. Langer-Gould in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Dr. Franziska Hopfner talks about the main takeaways from her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.

Dr. Jerzy Szaflarski talks about the FDA's approval of the first cannabis-derived pharmaceutical for the treatment of epilepsy and Lennox-Gastaut syndrome in particular. For more, read the full article, "The US Food and Drug Administration's Authorization of the First Cannabis-Derived Pharmaceutical: Are We Out of the Haze?" by Dr. Szaflarski in JAMA Neurology: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720. 

Co-director Dr. Brian Hainline talks about new features and highlights of the 2019 AAN Sports Concussion Conference. The conference takes place July 26-28 in Indianapolis.

Dr. Annette Langer-Gould discusses pregnancy and family planning with MS in the second part of a three-part series. To learn more, read the article "Pregnancy and Family Planning in Multiple Sclerosis" by Dr. Langer-Gould in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum.